Synthesis of cytokines during tumour development in mice immunized with the mycobacterial antigen complex A60

Scandinavian Journal of Immunology

Volumn 44, Issue 4, 1996, Pages 369-374

  Maes, H ^a   Cocito, C ^a,b  

^a UNIVERSITY OF LOUVAIN MEDICAL SCHOOL   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; IMMUNIZATION; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0029843911     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-318.x     Document Type: Article

References (44)

1. Oppenheim JJ, Ruscetti HN, Faltynek CR. Interleukins and interferons. In: Stites DP, Stobo JD, Wells JV, eds. Basic and Clinical Immunology. pp 82-95 Los Altos: Appleton and Lange, 1987.
2. Farrar JJ, Benjamin WR, Hilfiker ML, Howard M, Farrar WL, Fuller-Farrar J. The biochemistry, biology, and role of interleukin 2 in the induction of cytotoxic T cell and antibody-forming B cell responses. Immunological Rev 1982;63:129-66.
3. Bertagnolli MM, Herrmann SH, Pino VM, Schoff DD, Eberlein TJ. Approaches to immunotherapy of cancer: characterization of lymphokines as second signal for cytotoxic T-cell generation. Surgery 1991;110:459-68.
4. + tumor-infiltrating lymphocytes. J Exp Med 1991;173:647-58.
5. Cox GW, Melillo G, Chattopadhyay U, Mullet D, Fertel RH, Varesio L. Tumor necrosis factor-α-dependent production of reactive nitrogen intermediates mediates IFN-γ plus IL-2-induced murine macrophage tumoricidul activity. J Immunol 1992;149:3290-6.
6. Trinchieri G. Biology of natural killer cells. Adv Immunol 1989;47:187-376.
7. Levy R, Miller RA. Tumor therapy with monoclonal antibodies. Fed Proc 1983;42:2650-6.
8. Mule JJ, Shu S, Schwanz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984;225:1487-9.
9. Brunda MJ, Tarnowski D, Davatelis V. Interaction of recombinant interferons with recombinant interleukin-2, differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer 1986;37:787-93.
10. Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 1988;48:260-4.
11. Balkwil FR. Cytokines in Cancer Therapy. Oxford: Oxford University Press, 1989.
12. Dorr RT, Von Hoff DD. Cancer Chemotherapy Handbook. 2nd Edition, Norwalk: Appleton and Lange, 1994.
13. Baars JW, Wagstaff J, Boven E et al. Phase I study on the sequential administration of recombinant human interferon-γ and recombinant human interleukin-2 in patients with metastatic solid tumors. J Natl Cancer Inst 1991;83:1408-10.
14. Maes H, Taper H, Cocito C. Alteration of the immune response during cancer development and prevention by administration of a mycobacterial antigen. Scand J Immunol 1995;41:53-64.
15. Cocito C, Baelden MC, Benoit C. Immunological properties of antigen 60 of BCG: induction of humoral and cellular immune reactions. Scand J Immunol 1987;25:579-85.
16. Hubbard RD, Flory CM, Collins IM, Cocilo C. Immunization of mice with the A60 of Mycobacterium bovis BCG. Clin Exp Immunol 1992;88:129-31.
17. Cocito C, Vanlinden F. Preparation and properties of antigen A60 from Mycobacterium bovis BCG. Clin Exp Immunol 1986;66:262-72.
18. Closs O, Harboe M, Axelsen NH, Burch-Christensen K, Magnusson M. The antigen of Mycobacterium bovis, strain BCG, studied by cross immunoelectrophoresis: a reference system. Scand J Immunol 1980;12:249-63.
19. Cocito C, Vanlinden F. Composition and immunoreactivity of the A60 complex and other cell wall fractions from Mycobacterium bovis BCG. Scand J Immunol 1995;41:179-87.
20. Rockwell SC, Kallmn RF, Fajardo LP. Characteristics of a serially transplanted mouse mammary tumor and its tissue-culture-adapted derivative. J Natl Cancer Inst 1972;49:735-49.
21. Bennett JA, Gruff H, McKeally MF, Zelterman D, Crispen RG. Differences in biological activity among batches of lyophilized Tice Bacillus Calmette-Guérin and their association with clinical course in stage I lung cancer. Cancer Res 1983;43:4183-90.
22. Morales A. Long-term results and complications of intracavitary Bacillus Calmette-Guérin therapy for bladder cancer. J Urol 1984;132:457-9.
23. Palayew M, Briedis D, Libman M, Michel RP, Levy RD. Disseminated infection after intravesical BCG immunotherapy. Detection of organisms in pulmonary tissue. Chest 1993;104:307-9.
24. Ribi EE, Meyer TJ, Azuma I, Zbar B. Mycobacterial cell wall components in tumor suppression and regression. Natl Cancer Inst Monogr 1973;39:115-9.
25. Bessler WG, Kleine B, Martinez-Alonso C et al. Biological activity of bacterial surface components: bacterial extracts and defined bacterial cell wall components as immunomodulators. Lung 1990;168 Suppl:707-15.
26. Moreno C, Taverne J, Mehlert A et al. Lipoarabinomannan from Mycobacteriurn tuberculosis induces the production of tumor necrosis factor from human and murine macrophages. Clin Exp Immunol 1989;76:240-5.
27. Sibley LD, Hunter SW, Brennan PJ, Krahenbuhl JL. Mycobacterial lipoarabinomannan inhibits interferon-mediated activation of macrophages. Infect Immun 1988;56:1232-6.
28. Chan J, Fujiwara T, Brennan P et al. Microbial glycolipids: possible virulence factors that scavenge oxygen radicals. Proc Natl Acad Sci USA 1989;86:2453-7.
29. Coetsier C, Baelden MC, Coene M, Cocito C. Immunological analysis of the components of the antigen complex A60 of Mycobacterium bovis BCG. Clin Diag Lab Immunol 1994;1: 139-44.
30. Maes H, Taper H, Cocito C. Comparison between BCG and the A60 mycobacterial complex as cancer preventive immunotherapies. J Cancer Res Clin Oncol 1996;122:296-300.
31. Maes H, Cocito C. In vitro analysis of cancer prevention by a mycobacterial antigen complex and of cancer-promoted inhibition of immune reactions. J Cancer Res Clin Oncol 1996;(in press).
32. Miescher S, Whiteside TL, De Tribolet N, Von Fliedner V. In situ characterization, clonogenic potential, and antitumor cytolytic activity of T lymphocytes infiltrating human brain cancer cells. J Neurosurg 1988;68:438-48.
33. Shimiku Y, Weidmann E, Iwatsuki Y, Herberman RB, Whiteside TL. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma. Cancer Res 1991;51: 6153-62.
34. Karpati RM, Banks SM, Malissen B et al. Phenotypic characterization of murine tumor-infiltrating T lymphocytes. J Immunol 1991;146:2043-51.
35. Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today 1988;9:58-62.
36. Tuttle TM, McCrady CW, Inge TH, Salour M, Bear HD. γ-interferon plays a key role in T-cell-induced tumor regression. Cancer Res 1993;53:833-9.
37. Gresser I. Antitumor effects of interferon. Adv Cancer Res 1972;16:97-140.
38. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-71.
39. Haranaka KH, Satomi N, Sakurai A. Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 1984;34:263-7.
40. Merritt WD, Bailey JM, Pluznik DH. Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol 1984;89:1-10.
41. Dummer R, Posseckert G, Nestle F et al. Soluble interleukin-2 receptors inhibit interleukin-2 dependent proliferation and cytotoxicity: explanation for diminished natural killer cell activity in cutaneous T-cell lymphomas in vivo? J Invest Dermatol 1992;98:50-4.
42. Gelber C, Eisenbach L, Feldman M, Goodenow RS. T-cell subset analysis of Lewis Lung carcinoma tumor rejection: heterogeneity of effectors and evidence for negative regulatory lymphocytes correlating with metastasis. Cancer Res 1992;52:6507-15.
43. Roszman T, Elliott L, Brooks W. Modulation of T-cell function by gliomas. Immunol Today 1991;12:370-4.
44. Mizoguchi H, O'Shea J, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alteration in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.